Cannatrek
Cannatrek is an Australian vertically integrated medicinal cannabis company that cultivates, manufactures, and distributes cannabis flower and oil products through prescriber-mediated SASB and Authorised Prescriber pathways, serving AHPRA-registered doctors, nurse practitioners, pharmacists, and patients via a prescriber portal, telehealth services, and compassionate access programs.
- Company typePrivate
- Founded2014
- HeadquartersBalaclava, Australia
- Headcount51–100
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Cannatrek does
Cannatrek is an Australian vertically integrated medicinal cannabis company that cultivates, manufactures, and distributes therapeutic cannabis products not registered on the Australian Register of Therapeutic Goods (ARTG). Its product portfolio comprises medicinal cannabis flower and oil formulations, accessed exclusively through TGA-regulated Special Access Scheme (SASB) and Authorised Prescriber pathways. The company targets AHPRA-registered prescribers (doctors and nurse practitioners) as its primary go-to-market audience, supported by a web-based Prescriber Portal offering product information, SASB and Authorised Prescriber pathway application assistance, RACGP-approved education, and a Medical Science Liaison Team for clinical engagement. Pharmacists serve as a secondary dispensing channel, with integrations including the greenship.com.au pharmacy platform.
The company's revenue model operates through prescriber-mediated access for treatment-resistant patients, supplemented by Telehealth Services for direct patient consultations and the CASP (Compassionate Access to Care Scheme) for compassionate patient access. Cannatrek is privately held (ACN 056 175 369), headquartered in Balaclava, Victoria, with operations governed under Queensland jurisdiction. In January 2026, the company announced an all-stock merger with Little Green Pharma to create a combined group with approximately A$112 million in revenue and around 80 staff, positioning the merged entity as one of the largest vertically integrated cannabis businesses globally. Customer-facing go-to-market is sales-led and prescriber-focused, with the prescriber portal, medical science liaison outreach, and RACGP-approved education forming the core commercial engine. Pricing is not publicly disclosed, reflecting the regulated nature of the channel and the absence of direct consumer retail distribution.
Cannatrek firmographics
Firmographics- Name
- Cannatrek
- Legal name
- Cannatrek Limited
- Website
- https://cannatrek.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Cannatrek is an Australian vertically integrated medicinal cannabis company that cultivates, manufactures, and distributes cannabis flower and oil products through prescriber-mediated SASB and Authorised Prescriber pathways, serving AHPRA-registered doctors, nurse practitioners, pharmacists, and patients via a prescriber portal, telehealth services, and compassionate access programs.
- Ownership category
- akta.pro rank
Cannatrek industry classification
Industry- Product category
- Medicinal Cannabis Manufacturing
- NAICS
- Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Medical Cannabis Dispensaries (CRANAFAB)
- akta.pro secondary industry
- Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)
Keywords
Where Cannatrek is headquartered
LocationHeadquarters
- HQ city
- Balaclava
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Cannatrek business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Medicinal cannabis products and services: Cannatrek supplies medicinal cannabis goods and services. The company operates through prescriber-mediated access pathways (SASB and Authorised Prescriber schemes), with products prescribed to treat specific conditions or symptoms where patients are treatment-resistant to recommended ARTG-registered treatments.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Cannatrek product offering
Product offeringCore offering
Cannatrek cultivates, manufactures, and distributes medicinal cannabis products (flower and oil formulations) in Australia. Products are not registered on the Australian Register of Therapeutic Goods (ARTG) and are accessed via the Special Access Scheme (SASB) or Authorised Prescriber pathways. The company also operates a prescriber portal providing healthcare practitioners with regulatory pathway assistance and RACGP-approved education.
Product overview
Cannatrek is an Australian medicinal cannabis company operating as a vertically integrated business. The company offers a portfolio of medicinal cannabis products (flower and oil formulations), a prescriber portal for healthcare providers with resources and pathway assistance, and telehealth consultation services. The CASP program provides compassionate access to care. Cannatrek products are not registered on the ARTG and must be prescribed via Authorised Prescriber or Special Access Scheme pathways. The company has agreed to merge with Little Green Pharma in an all-stock transaction to create a combined entity with A$112 million in revenue.
Differentiator
Problem solved
Functional benefit
Products and services
- Medicinal Cannabis Products
Companies that use Cannatrek
Customer profileSegments3 records
Ideal customer profiles3 records
Cannatrek technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Cannatrek partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Little Green PharmacoreAustralian medicinal cannabis companies Little Green Pharma and Cannatrek agreed to merge in an all-stock transaction creating a combined group with A$112 million in revenue and approximately 80 staff, positioning the entity as one of the largest vertically integrated cannabis businesses globally.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
Cannatrek competitors and assessment
Company assessmentDirect peers
- Little Green Pharma: Australian medicinal cannabis cultivator, manufacturer, and distributor that is merging with Cannatrek in an all-stock deal. Operates in the same Australian regulatory framework (SASB/Authorised Prescriber), making it the most direct comparable as the merger counterparty.
- Althea Group Holdings: Australian medicinal cannabis company producing and distributing THC and CBD products via similar prescriber and pharmacy channels. Directly competes with Cannatrek for Australian prescriber relationships and patient access.
- AusCann Group Holdings: Australian medicinal cannabis company focused on developing, producing, and supplying cannabinoid-based pharmaceuticals. Targets the same AHPRA prescriber channel and competes for similar patient indications.
- Incannex Healthcare: Australian clinical-stage medicinal cannabis and psychedelic pharmaceutical developer. Overlaps with Cannatrek on medicinal cannabis distribution and shares exposure to TGA-regulated prescriber pathways.
- BOD Australia: Australian medicinal cannabis and hemp-derived CBD product company selling through healthcare professionals and pharmacies. Comparable prescriber-focused distribution model in the same regulatory environment.
Emerging players
- MGC Pharmaceuticals: Australia-listed medicinal cannabis company with operations spanning Europe and Australia. Comparable in product category but operates at smaller scale and across multiple geographies, making it an emerging rather than direct peer.
- Zelira Therapeutics: Australian-listed company developing clinically validated cannabinoid-based medicines. Comparable therapeutic-goods positioning but more R&D-focused and earlier-stage in commercial distribution than Cannatrek.
Broad incumbents
- Tilray Brands: Global vertically integrated cannabis company with cultivation, processing, and distribution across multiple continents including Australia. Much larger incumbent that overlaps with Cannatrek on medicinal cannabis products and pharmacy distribution.
- Aurora Cannabis: Global cannabis producer with medicinal cannabis operations in multiple countries. A broad incumbent peer with overlapping medicinal product lines and prescriber-channel distribution, though much larger and more diversified than Cannatrek.
- Canopy Growth Corporation: Large global cannabis company with established medicinal cannabis brands distributed via pharmacies and prescribers. Broad incumbent that competes for the same medicinal patient populations as Cannatrek in markets where it operates.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Cannatrek social profiles
Digital presenceCannatrek compliance and trust
Trust signalCompliance1 record
Cannatrek financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cannatrek leadership team
Management profileNumber of profiles
Cannatrek funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cannatrek M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cannatrek
What does Cannatrek do?
Cannatrek cultivates, manufactures, and distributes medicinal cannabis products (flower and oil formulations) in Australia. Products are not registered on the Australian Register of Therapeutic Goods (ARTG) and are accessed via the Special Access Scheme (SASB) or Authorised Prescriber pathways. The company also operates a prescriber portal providing healthcare practitioners with regulatory pathway assistance and RACGP-approved education.
Is Cannatrek a public or private company?
Cannatrek is a private company. It is classified as unknown and is currently operating.
When was Cannatrek founded?
Cannatrek was founded in 2014. It employs 51 to 100 people.
Where is Cannatrek based?
Cannatrek is headquartered in Balaclava, Australia, in the Oceania region.
How does Cannatrek make money?
One revenue line is on record: medicinal cannabis products and services.
Who are Cannatrek's main competitors?
Direct peers on record are Little Green Pharma, Althea Group Holdings, AusCann Group Holdings, Incannex Healthcare and BOD Australia. Emerging players are MGC Pharmaceuticals and Zelira Therapeutics. Broad incumbents are Tilray Brands, Aurora Cannabis and Canopy Growth Corporation.
Does Cannatrek have an API?
No public API is recorded for Cannatrek.
What industry is Cannatrek in?
Cannatrek's product category is Medicinal Cannabis Manufacturing. Its primary akta.pro industry code is CRANAFAB, Medical Cannabis Dispensaries, with a secondary code of CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services). Its NAICS code is 325411 and its SIC code is 2833.